21+
Age Verification
You must be 21 years of age or older to enter this site.
By entering, you confirm you are 21 years of age or older.
You must be 21 years of age or older to enter this site.
By entering, you confirm you are 21 years of age or older.
GLP3-RT is a novel triple-acting receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. This compound represents the next generation of incretin-based research peptides, distinguished by its unique tri-agonist mechanism that engages three distinct metabolic pathways in a single molecular entity.
Synthesized as a 39-amino acid peptide, retatrutide features a C20 fatty diacid moiety conjugated via a linker to lysine at position 17, enabling extended pharmacokinetic profiles in preclinical models. The compound has been the subject of multiple peer-reviewed Phase I and Phase II clinical studies evaluating its receptor binding characteristics and in-vivo activity profiles.
AXOM GLP3-RT is manufactured under strict cGMP-equivalent protocols and verified to ≥99% purity via reverse-phase HPLC. Each lot is accompanied by a Certificate of Analysis documenting identity, purity, peptide content, and endotoxin levels. Available in 10mg, 20mg, 30mg, and 40mg lyophilized formats.
Targets GIP, GLP-1, and glucagon receptors — three distinct metabolic pathways in a single compound for comprehensive in-vitro research applications.
C20 fatty diacid conjugation enables prolonged receptor engagement in preclinical pharmacokinetic studies compared to native peptide analogues.
≥99% HPLC-verified purity with full COA documentation. Every lot independently tested by third-party analytical laboratories.
Phase 2 study evaluating retatrutide across multiple concentrations in subjects with type 2 diabetes. The triple agonist mechanism demonstrated significant receptor engagement across all three target pathways with dose-dependent activity profiles observed over 24 weeks.
Landmark phase 2 study examining retatrutide's tri-agonist activity in subjects with metabolic dysfunction. Demonstrated the unique pharmacological profile of simultaneous GIP, GLP-1, and glucagon receptor engagement in a controlled in-vivo setting.
First-in-human multiple ascending study characterizing the pharmacokinetic and pharmacodynamic profile of the triple agonist compound, establishing the foundational receptor binding and activity data for subsequent research applications.
| Product Name | GLP3-RT (Retatrutide) |
| Synonyms | LY3437943 |
| CAS Number | 2381089-83-2 |
| Molecular Formula | C187H291N49O57 |
| Molecular Weight | ~4,113.58 Da |
| Sequence Length | 39 amino acids |
| Receptor Targets | GIP, GLP-1, Glucagon (triple agonist) |
| Modification | C20 fatty diacid at Lys-17 via linker |
| Purity | ≥99% (Reverse-Phase HPLC) |
| Form | Lyophilized white powder |
| Available Sizes | 10mg, 20mg, 30mg, 40mg |
| Solubility | Soluble in sterile water, bacteriostatic water |
| Endotoxin | <1 EU/μg (LAL method) |
| Certification | COA included with every order |
| Intended Use | For research and laboratory use only |
GLP3-RT is supplied as a lyophilized powder and should be reconstituted with sterile bacteriostatic water (BAC water) for research applications.
All orders ship within the continental United States via USPS or UPS. Peptides are shipped at ambient temperature — lyophilized peptides are stable during transit. Free shipping on orders over $250.
